Evaluation of the published kinase inhibitor set to identify multiple inhibitors of bacterial ATP-dependent mur ligases

References

• Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007;6:29–40.
   PubMed Web of Science ®Google Scholar
• Brown ED, Wright GD. Antibacterial drug discovery in the resistance era. Nature 2016;529:336–43.
   PubMed Web of Science ®Google Scholar
• Kinch MS, Patridge E, Plummer M, Hoyer D. An analysis of FDA-approved drugs for infectious disease: antibacterial agents. Drug Discov Today 2014;19:1283–7.
   PubMed Web of Science ®Google Scholar
• Gwynn MN, Portnoy A, Rittenhouse SF, Payne DJ. Challenges of antibacterial discovery revisited. Ann NY Acad Sci 2010;1213:5–19.
   PubMed Web of Science ®Google Scholar
• Smith CA. Structure, function and dynamics in the Mur family of bacterial cell wall ligases. J Mol Biol 2006;362:640–55.
   PubMed Web of Science ®Google Scholar
• Mengin-Lecreulx D, Flouret B, van Heijenoort J. Cytoplasmic steps of peptidoglycan synthesis in Escherichia coli. J Bacteriol 1982;151:1109–17.
   PubMed Web of Science ®Google Scholar
• Hrast M, Sosič I, Šink R, Gobec S. Inhibitors of the peptidoglycan biosynthesis enzymes MurA-F. Bioorg Chem 2014;55:2–15.
   PubMed Web of Science ®Google Scholar
• Barreteau H, Kovač A, Boniface A, et al. Cytoplasmic steps of peptidoglycan biosynthesis. FEMS Microbiol Rev 2008;32:168–207.
   PubMed Web of Science ®Google Scholar
• Kouidmi I, Levesque RC, Paradis-Bleau C. The biology of Mur ligases as an antibacterial target. Mol Microbiol 2014;94:242–53.
   PubMed Web of Science ®Google Scholar
• El Zoeiby A, Sanschagrin F, Levesque RC. Structure and function of the Mur enzymes: development of novel inhibitors. Mol Microbiol 2003;47:1–12.
   PubMed Web of Science ®Google Scholar
• Hrast M, Turk S, Sosič I, others, et al. Structure-activity relationships of new cyanothiophene inhibitors of the essential peptidoglycan biosynthesis enzyme MurF. Eur J Med Chem 2013;66:32–45.
   PubMed Web of Science ®Google Scholar
• Šink R, Barreteau H, Patin D, et al. MurD enzymes: some recent developments. Biomol Concepts 2013;4:539–56.
   PubMedGoogle Scholar
• Barreteau H, Sosič I, Turk S, et al. MurD enzymes from different bacteria: evaluation of inhibitors. Biochem Pharmacol 2012;84:625–32.
   PubMed Web of Science ®Google Scholar
• Zidar N, Tomašić T, Šink R, et al. Discovery of novel 5-benzylidenerhodanine and 5-benzylidenethiazolidine-2,4-dione inhibitors of MurD ligase. J Med Chem 2010;53:6584–94.
   PubMed Web of Science ®Google Scholar
• Zidar N, Tomašić T, Šink R, et al. New 5-benzylidenethiazolidin-4-one inhibitors of bacterial MurD ligase: design, synthesis, crystal structures, and biological evaluation. Eur J Med Chem 2011;46:5512–23.
   PubMed Web of Science ®Google Scholar
• Tomašić T, Šink R, Zidar N, et al. Dual inhibitor of MurD and MurE ligases from Escherichia coli and Staphylococcus aureus. ACS Med Chem Lett 2012;3:626–30.
   PubMed Web of Science ®Google Scholar
• Perdih A, Hrast M, Barreteau H, et al. Benzene-1,3-dicarboxylic acid 2,5-dimethylpyrrole derivatives as multiple inhibitors of bacterial Mur ligases (MurC–MurF). Bioorg Med Chem 2014;22:4124–34.
   PubMed Web of Science ®Google Scholar
• Brown DG, Boström J. Where do recent small molecule clinical development candidates come from? J Med Chem 2018;61:9442–68.
   PubMed Web of Science ®Google Scholar
• Proschak E, Stark H, Merk D. Polypharmacology by design: a medicinal chemist’s perspective on multitargeting compounds. J Med Chem 2019;62:420–44.
   PubMed Web of Science ®Google Scholar
• Škedelj V, Tomašić T, Mašič LP, Zega A. ATP-binding site of bacterial enzymes as a target for antibacterial drug design. J Med Chem 2011;54:915–29.
   PubMed Web of Science ®Google Scholar
• Wong KK, Kuo DW, Chabin RM, et al. Engineering a cell-free murein biosynthetic pathway: combinatorial enzymology in drug discovery. J Am Chem Soc 1998;120:13527–8.
   Web of Science ®Google Scholar
• Chappelle EW, Levin GV. Use of the firefly bioluminescent reaction for rapid detection and counting of bacteria. Biochem Med 1968;2:41–52.
   Google Scholar
• Traut TW. Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 1994;140:1–22.
   PubMed Web of Science ®Google Scholar
• Lanzetta PA, Alvarez LJ, Reinach PS, Candia OA. An improved assay for nanomole amounts of inorganic phosphate. Anal Biochem 1979;100:95–7.
   PubMed Web of Science ®Google Scholar
• Liger D, Masson A, Blanot D, et al. Over-production, purification and properties of the uridine-diphosphate-N-acetylmuramate: l-alanine ligase from Escherichia coli. Eur J Biochem 1995;230:80–7.
   PubMedGoogle Scholar
• Auger G, Martin L, Bertrand J, et al. Large-scale preparation, purification, and cristallization of UDP-N-acetylmuramoyl-l-alanine: d-glutamate ligase from Escherichia coli. Protein Expr Purif 1998;13:23–9.
   PubMed Web of Science ®Google Scholar
• Gordon E, Flouret B, Chantalat L, et al. Crystal structure of UDP-N-acetylmuramoyl-l-alanyl-d-glutamate: meso-diaminopimelate ligase from Escherichia coli. J Biol Chem 2001;276:10999–1006.
   PubMed Web of Science ®Google Scholar
• Dementin S, Bouhss A, Auger G, et al. Evidence of a functional requirement for a carbamoylated lysine residue in MurD, MurE and MurF synthetases as established by chemical rescue experiments. Eur J Biochem 2001;268:5800–7.
   PubMedGoogle Scholar
• Wayne PA, CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard—Tenth edition. CLSI Document M07-A10. Clinical and Laboratory Standards Institute, 2015.
   Google Scholar
• The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 5.0, 2015. Available from: http://www.eucast.org.
   Google Scholar
• Simčič M, Sosič I, Hodošček M, et al. The binding mode of second-generation sulfonamide inhibitors of MurD: clues for rational design of potent MurD inhibitors. PLoS ONE 2012;7:e52817.
   PubMed Web of Science ®Google Scholar
• Cavanagh J, Fairbrother WJ, Palmer AG, et al. Protein NMR spectroscopy: principles and practice. 2nd ed. San Diego, USA: Academic Press; 2007.
   Google Scholar
• McDonald O, Lackey K, Davis-Ward R, et al. Aza-stilbenes as potent and selective c-RAF inhibitors. Bioorg Med Chem Lett 2006;16:5378–83.
   PubMed Web of Science ®Google Scholar
• Waterson AG, Stevens KL, Reno MJ, et al. Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors. Bioorg Med Chem Lett 2006;16:2419–22.
   PubMed Web of Science ®Google Scholar
• Stevens KL, Reno MJ, Alberti JB, et al. Synthesis and evaluation of pyrazolo[1,5-b]pyridazines as selective cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett 2008;18:5758–62.
   PubMed Web of Science ®Google Scholar
• Boehm JC, Bower MJ, Gallagher TF, et al. Phenoxypyrimidine inhibitors of p38α kinase: synthesis and statistical evaluation of the p38 inhibitory potencies of a series of 1-(piperidin-4-yl)-4-(4-fluorophenyl)-5-(2-phenoxypyrimidin-4-yl) imidazoles. Bioorg Med Chem Lett 2001;11:1123–6.
   PubMed Web of Science ®Google Scholar
• Chamberlain SD, Wilson JW, Deanda F, et al. Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: potent inhibitors of the IGF-1R receptor tyrosine kinase. Bioorg Med Chem Lett 2009;19:469–73.
   PubMed Web of Science ®Google Scholar
• Hopkins AL, Groom CR, Alex A. Ligand efficiency: a useful metric for lead selection. Drug Discov Today 2004;9:430–1.
   PubMed Web of Science ®Google Scholar
• Murray CW, Erlanson DA, Hopkins AL, et al. Validity of ligand efficiency metrics. ACS Med Chem Lett 2014;5:616–8.
   PubMed Web of Science ®Google Scholar
• Leeson PD, Young RJ. Molecular property design: does everyone get it? ACS Med Chem Lett 2015;6:722–5.
   PubMed Web of Science ®Google Scholar
• Elkins JM, Fedele V, Szklarz M, et al. Comprehensive characterization of the published kinase inhibitor set. Nat Biotechnol 2016;34:95–103.
   PubMed Web of Science ®Google Scholar
• Zega A. NMR methods for identification of false positives in biochemical screens. J Med Chem 2017;60:9437–47.
   PubMed Web of Science ®Google Scholar
• Arsovska E, Mali G, Golič Grdadolnik S, Zega A. NMR in the design of antibacterials. Curr Med Chem 2014;21:4328–46.
   PubMed Web of Science ®Google Scholar
• Simčič M, Pureber K, Kristan K, et al. A novel 2-oxoindolinylidene inhibitor of bacterial MurD ligase: enzyme kinetics, protein-inhibitor binding by NMR and a molecular dynamics study. Eur J Med Chem 2014;83:92–101.
   PubMed Web of Science ®Google Scholar
• Sosič I, Barreteau H, Simčič M, et al. Second-generation sulfonamide inhibitors of d-glutamic acid-adding enzyme: activity optimisation with conformationally rigid analogues of d-glutamic acid. Eur J Med Chem 2011;46:2880–94.
   PubMed Web of Science ®Google Scholar
• Bertrand JA, Auger G, Fanchon E, et al. Crystal structure of UDP-N-acetylmuramoyl-l-alanine: d-glutamate ligase from Escherichia coli. Embo J 1997;16:3416–25.
   PubMed Web of Science ®Google Scholar
• Bertrand JA, Auger G, Martin L, et al. Determination of the MurD mechanism through crystallographic analysis of enzyme complexes. J Mol Biol 1999;289:579–90.
   PubMed Web of Science ®Google Scholar
• Bertrand JA, Fanchon E, Martin L, et al. “Open” structures of MurD: domain movements and structural similarities with folylpolyglutamate synthetase. J Mol Biol 2000;301:1257–66.
   PubMed Web of Science ®Google Scholar
• Gaulton A, Hersey A, Nowotka M, et al. 'The ChEMBL database in 2017.' Nucleic Acids Res 2017;45:D945–54.
   PubMed Web of Science ®Google Scholar